Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer
Changqing Xie(National Institutes of Health), Tim F. Greten(National Cancer Institute), David E. Kleiner(National Institutes of Health), Donna Mabry‐Hrones(National Institutes of Health), David Venzon(National Institutes of Health), Firouzeh Korangy(United States Department of Health and Human Services), Bradford J. Wood(National Institutes of Health), Manoj Tyagi(National Institutes of Health), Suzanne Fioravanti(National Institutes of Health), Seth M. Steinberg(National Institutes of Health), Jun S. Wei(Center for Cancer Research), Charalampos S. Floudas(National Cancer Institute), Victoria Anderson(Newcastle upon Tyne Hospitals NHS Foundation Trust), David Agdashian(National Institutes of Health), Austin G. Duffy(Mater Misericordiae University Hospital), Vineela Gangalapudi(National Cancer Institute), Venkatesh Krishnasamy(National Institutes of Health), Melissa Walker(Ottawa Hospital), William D. Figg(National Cancer Institute), Gagandeep Brar(City of Hope), Elliot Levy(National Institutes of Health), Javed Khan(Kent State University), Milan Sandhu(National Institutes of Health), Maria Pia Morelli(The University of Texas MD Anderson Cancer Center)
Cited by 103
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k